



NEWS RELEASE

## Aptinyx to Host PTSD-Focused R&D Day on August 5th, 2020

7/8/2020

Program to feature presentation from Dr. Murray Stein, Distinguished Professor of Psychiatry at UCSD and board-certified psychiatrist

Aptinyx expects data from exploratory Phase 2 study of NYX-783 in PTSD in late 2020

EVANSTON, Ill.--(BUSINESS WIRE)-- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it will host a virtual R&D Day focused on the company's development efforts in post-traumatic stress disorder (PTSD) on Wednesday, August 5, 2020, from 10:00 a.m. to 11:30 a.m. ET.

The meeting will feature a presentation from Murray B. Stein MD, MPH, FRCPC. Dr. Stein is Distinguished Professor of Psychiatry and Family Medicine & Public Health and Vice Chair for Clinical Research in Psychiatry at the University of California San Diego (UCSD). He is also a Staff Psychiatrist at the VA San Diego Healthcare System. Dr. Stein will be available to answer questions following the event.

The R&D day will also feature presentations by members of Aptinyx's management team, who will provide an overview of the progress of NYX-783, the company's novel NMDA receptor modulator in clinical development for the treatment of PTSD. Last month, Aptinyx announced the completion of enrollment in its ongoing Phase 2 exploratory study of NYX-783 in patients with PTSD. The company anticipates reporting data from the study in late 2020.

### Video Webcast Information

A live video webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media"

section of Aptinyx's website at <https://ir.aptinyx.com>. A replay of the webcast will be archived on Aptinyx's website following the event.

## About Post-Traumatic Stress Disorder

Approximately eight and a half million people in the United States suffer from PTSD, which is characterized by intrusive symptoms, avoidance, negative alteration in cognition and mood, hyperarousal, and/or arousal alterations following the experience of trauma. PTSD can result from various forms of trauma, including combat exposure, car accidents, sexual or other physical assault, abuse, natural disasters, and others. The lifetime prevalence of PTSD is approximately seven percent in the general population but is much higher in populations at risk for exposure to trauma, such as military service members and first responders. In addition to the challenges associated with the direct symptoms, PTSD sufferers have a higher rate of suicide and often struggle with simultaneous addiction, leading to an even greater social and economic burden of the disorder. Available therapeutic options are limited, including only two approved conventional SSRI antidepressants, which have limited efficacy, undesirable side effects, and target only the symptoms of PTSD, not the underlying disorder itself.

## About NYX-783

NYX-783 is a novel, oral NMDA receptor modulator currently in Phase 2 development for the treatment of post-traumatic stress disorder (PTSD). In preclinical studies of NYX-783, particularly strong results were observed in psychiatric models, models of fear extinction, and models of substance abuse. In a Phase 1 clinical study of NYX-783, ample central nervous system exposure was observed and the product candidate demonstrated a favorable safety and tolerability profile, with no serious adverse effects, across a wide dose range. The U.S. Food and Drug Administration has granted Fast Track designation to the development of NYX-783 for the treatment of PTSD.

## About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson's disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit [www.aptinyx.com](http://www.aptinyx.com).

## Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the company’s business plans and objectives, including future plans or expectations for NYX-783 and potential therapeutic effects of NYX-783, expectations regarding the design, implementation, timing, and success of its current and potential clinical studies of NYX-783, the timing for the company’s receipt and announcement of data from its exploratory study of NYX-783, and expectations regarding its preclinical development activities. Risks that contribute to the uncertain nature of the forward-looking statements include: the effect of COVID-19 on our business and financial results, including with respect to disruptions to our clinical trials, business operations, and ability to raise additional capital; the success, cost, and timing of the company’s product candidate development activities and planned clinical studies; the company’s ability to execute on its strategy; that positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; regulatory developments in the United States and foreign countries; the company’s estimates regarding expenses, future revenue, and capital requirements; as well as those risks and uncertainties set forth in the company’s most recent annual report on Form 10-K and subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aptinyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Source: Aptinyx Inc.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200708005275/en/): <https://www.businesswire.com/news/home/20200708005275/en/>

### Investor & Media Contact:

Nick Smith

Aptinyx Inc.

[ir@aptinyx.com](mailto:ir@aptinyx.com) or [corporate@aptinyx.com](mailto:corporate@aptinyx.com)

847-871-0377

Source: Aptinyx Inc.